MAPK8 and cardiac hypertrophy: These data indicated that SF can control the cardiac hypertrophy caused by AngII in a time- and dose-dependent manner and this effect can be blocked by ERK agonists which demonstrated that SF can inhibit cardiac myocyte hypertrophy by regulating MAPK/ERK and JNK pathways.